Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

GT Biopharma Inc (GTBP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 99,918
  • Shares Outstanding, K 47,580
  • Annual Sales, $ 0 K
  • Annual Income, $ -143,250 K
  • 36-Month Beta -5.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.39
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -8.62
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/13/18
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6900 +24.26%
on 09/18/18
2.3900 -12.13%
on 09/04/18
+0.1050 (+5.26%)
since 08/21/18
3-Month
1.3400 +56.72%
on 07/10/18
2.8000 -25.00%
on 07/25/18
+0.0600 (+2.94%)
since 06/21/18
52-Week
1.1900 +76.47%
on 05/04/18
7.5500 -72.19%
on 10/20/17
-3.9500 (-65.29%)
since 09/21/17

Most Recent Stories

More News
GT Biopharma Announces Postive Results For Two Next Generation Trikes In Solid Tumors

LOS ANGELES, CA / ACCESSWIRE / September 13, 2018 / GT Biopharma Inc. (OTCQB: GTBP) and (Euronext Paris: GTBP) announced today the positive results for two next generation Trispecific Killer Engagers (TriKEs)...

GTBP : 2.1000 (+5.00%)
GT Biopharma's Chairman and Chief Executive Officer Raymond W Urbanski, M.D., Ph.D Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration

LOS ANGELES , August 30, 2018 /PRNewswire/ --

GTBP : 2.1000 (+5.00%)
GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration

GT Biopharma Inc. (OTC: GTBP) (Euronext Paris: GTBP.PA) is an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary NK-engager and Bispecific Antibody...

GTBP : 2.1000 (+5.00%)
AMGN : 205.10 (unch)
GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration

LOS ANGELES , August 29, 2018 /PRNewswire/ --

GTBP : 2.1000 (+5.00%)
GT Biopharma Announces GTBP CEO, Dr. Raymond Urbanski, to Make Presentation at the 2018 Wedbush PacGrow Healthcare Conference

LOS ANGELES , August 14, 2018 /PRNewswire/ --

GTBP : 2.1000 (+5.00%)
GT Biopharma Announces Completion of $5.1 Million Convertible Debt Financing

LOS ANGELES, CA / ACCESSWIRE / August 7, 2018 / GT Biopharma Inc. (OTCQB: GTBP; Euronext Paris: GTBP) an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary...

GTBP : 2.1000 (+5.00%)
GT Biopharma Launches Shareholder Communications Initiative

LOS ANGELES, CA / ACCESSWIRE / July 20, 2018 / GT Biopharma Inc. (OTCQB: GTBP) (Euronext Paris: GTBP) announced today the launch of an expanded shareholder communications initiative designed to improve...

GTBP : 2.1000 (+5.00%)
GT Biopharma Inc. Announces Agreement with a Major Pharmaceutical Company to Study its Drug Candidate OXS-1550 in Combination With a Multi-Billion Dollar Oncology Drug

LOS ANGELES , July 19, 2018 /PRNewswire/ --

GTBP : 2.1000 (+5.00%)
Seasoned Financial Executive Federica O'Brien Joins GT Biopharma's Board of Directors

LOS ANGELES , April 26, 2018 /PRNewswire/ --

GTBP : 2.1000 (+5.00%)
These Biotech Stocks Have a Strong Green Close on Friday

CORAL GABLES, FL / ACCESSWIRE / March 29, 2018 / The biotechnology industry continued to recover on Thursday. The market itself had one of its most volatile weeks yet as the first quarter of 2018 came...

GALT : 6.53 (-5.77%)
GTBP : 2.1000 (+5.00%)
CELGZ : 1.57 (-1.87%)
JUNO : 86.96 (+0.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade GTBP with:

Key Turning Points

2nd Resistance Point 2.1667
1st Resistance Point 2.1333
Last Price 2.1000
1st Support Level 2.0333
2nd Support Level 1.9667

See More

52-Week High 7.5500
Fibonacci 61.8% 5.1205
Fibonacci 50% 4.3700
Fibonacci 38.2% 3.6195
Last Price 2.1000
52-Week Low 1.1900

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar